J

Jafron Biomedical Co Ltd
SZSE:300529

Watchlist Manager
Jafron Biomedical Co Ltd
SZSE:300529
Watchlist
Price: 30.32 CNY 0.83% Market Closed
Market Cap: 24.2B CNY
Have any thoughts about
Jafron Biomedical Co Ltd?
Write Note

Operating Margin
Jafron Biomedical Co Ltd

38%
Current
39%
Average
4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
38%
=
Operating Profit
1B
/
Revenue
2.6B

Operating Margin Across Competitors

Country CN
Market Cap 24.5B CNY
Operating Margin
38%
Country US
Market Cap 199B USD
Operating Margin
17%
Country US
Market Cap 191.3B USD
Operating Margin
26%
Country US
Market Cap 141.3B USD
Operating Margin
22%
Country US
Market Cap 134.2B USD
Operating Margin
18%
Country IE
Market Cap 104.6B USD
Operating Margin
19%
Country US
Market Cap 65.6B USD
Operating Margin
14%
Country DE
Market Cap 58.1B EUR
Operating Margin
12%
Country US
Market Cap 44.5B USD
Operating Margin
28%
Country CN
Market Cap 311.1B CNY
Operating Margin
36%
Country US
Market Cap 36.3B USD
Operating Margin
13%
No Stocks Found

Jafron Biomedical Co Ltd
Glance View

Market Cap
24.5B CNY
Industry
Health Care

In the heart of China's bustling Guangdong province, Jafron Biomedical Co., Ltd. has carved a distinguished niche in the world of biomedicine since its inception. This innovative company, recognized as a leader in the hemoperfusion field, has built its reputation on a foundation of pioneering blood purification technologies. By developing and manufacturing an array of hemoperfusion devices, Jafron offers critical solutions that aid in the removal of toxins from the bloodstream, thus improving outcomes for patients suffering from various systemic toxic reactions and kidney-related disorders. Their state-of-the-art hemoperfusion cartridges, meticulously designed for efficiency, are instrumental in managing and treating conditions such as chronic kidney disease and liver dysfunction. This relentless pursuit of quality is bolstered by a dedicated research division that harmonizes clinical insights with scientific innovation, ensuring Jafron stays at the forefront of clinical demand. Jafron Biomedical thrives on a robust business model that fuses direct sales with an expansive network of partnerships. This dual approach not only amplifies their market reach but also enables the company to establish solid footholds in key domestic and international markets. By collaborating with healthcare institutions and medical device distributors, Jafron ensures its products deliver critical health solutions to a broad clientele. The revenue streams are mainly anchored in the sales of its hemoperfusion products and through strategic expansions in emerging markets. As global health standards evolve and the demand for advanced medical solutions expands, Jafron is positioned to sustain its growth momentum by continually innovating in response to the global demand for efficient blood purification therapies. Through these methods, Jafron not only augments its economic footprint but also underscores its commitment to enhancing global healthcare standards.

Intrinsic Value
48.46 CNY
Undervaluation 37%
Intrinsic Value
Price
J

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
38%
=
Operating Profit
1B
/
Revenue
2.6B
What is the Operating Margin of Jafron Biomedical Co Ltd?

Based on Jafron Biomedical Co Ltd's most recent financial statements, the company has Operating Margin of 38%.